Zynex (OTCMKTS: ZYXI) is one of 46 public companies in the “Electromedical equipment” industry, but how does it contrast to its rivals? We will compare Zynex to similar businesses based on the strength of its institutional ownership, analyst recommendations, earnings, profitability, dividends, risk and valuation.
This is a summary of recent recommendations and price targets for Zynex and its rivals, as reported by MarketBeat.
||Strong Buy Ratings
As a group, “Electromedical equipment” companies have a potential upside of 21.68%. Given Zynex’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Zynex has less favorable growth aspects than its rivals.
Institutional and Insider Ownership
0.0% of Zynex shares are held by institutional investors. Comparatively, 40.7% of shares of all “Electromedical equipment” companies are held by institutional investors. 20.1% of shares of all “Electromedical equipment” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Zynex and its rivals top-line revenue, earnings per share and valuation.
Zynex’s rivals have higher revenue and earnings than Zynex. Zynex is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Risk & Volatility
Zynex has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, Zynex’s rivals have a beta of 1.57, suggesting that their average share price is 57% more volatile than the S&P 500.
This table compares Zynex and its rivals’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Zynex rivals beat Zynex on 9 of the 13 factors compared.
Zynex, Inc., a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence. The company also distributes private labeled products, such as electrodes for the delivery of electrical current to the body; batteries for use in electrotherapy products; Comfortrac for cervical traction; JetStream for hot/cold therapy; and LSO Back Braces for lumbar support. In addition, it develops non-invasive blood volume monitors for use in hospitals and surgery centers. The company offers its products for pain management and control; and stroke and spinal cord injury rehabilitation. It sells its products through direct and independent sales representatives primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.